NANOBIOTIX Sets to Showcase Innovations at Upcoming Conferences
NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX), a trailblazer in nanotherapeutic technology, will be actively participating in a series of notable investor conferences. The management team is determined to highlight their groundbreaking approaches to cancer treatment and engage with potential investors to discuss future strategies and developments.
Upcoming Conference Schedule
UBS Global Healthcare Conference
The UBS Global Healthcare Conference will take place on Monday, November 10. Bart van Rhijn, the Chief Financial & Business Officer, is set to present at 5 PM ET. The company anticipates drawing significant interest as they align their innovative solutions with market expectations.
Guggenheim's Annual Healthcare Innovation Conference
On the same day, Laurent Levy, the Chief Executive Officer, will lead discussions at the Guggenheim's Annual Healthcare Innovation Conference at 4:30 PM ET. This platform is a great opportunity to showcase how NANOBIOTIX is poised to transform oncological treatments and expand its reach.
Stifel Healthcare Conference
The Stifel Healthcare Conference will be another critical avenue for engagement, scheduled for Thursday, November 13, at 8 AM ET. Bart van Rhijn and Laurent Levy will address potential investors, expanding on the company's objectives and advancements in nanotechnology.
Virtual Access to Webcasts
For those unable to attend in person, NANOBIOTIX will provide live webcasts of the presentations. These will be accessible through the events page on the company’s website. Additionally, recordings will be made available afterward, allowing a broader audience to tap into valuable insights from the management.
Company Overview: Pioneering Nanotechnology
Founded in 2003, NANOBIOTIX is at the forefront of biotechnology, specializing in harnessing the potential of nanotechnology to revolutionize cancer treatments. The company's headquarters in Paris serves as a hub for innovations driven by a passionate team committed to enhancing treatment possibilities for patients. With significant expansions to the Nasdaq Global Select Market, NANOBIOTIX is rapidly gaining recognition on an international scale.
Groundbreaking Technologies and Patents
NANOBIOTIX boasts more than 25 patent families across three key platforms, targeting oncology, bioavailability, and central nervous system disorders. Their cutting-edge research aims to advance treatment modalities and improve overall patient outcomes through disruptive technology.
Contact Information
For further inquiries or to engage with the company, potential investors and media can reach out to the dedicated communication and investor relations teams. Brandon Owens is available at +1 (617) 852-4835 for communications. Joanne Choi, who leads investor relations in the US, can be contacted at +1 (713) 609-3150.
Furthermore, Ricky Bhajun is available for inquiries related to the European market at +33 (0) 79 97 29 99. The company encourages open communication as it continues to build its future.
Frequently Asked Questions
What is NANOBIOTIX's main focus?
NANOBIOTIX focuses on developing innovative nanotherapeutic solutions aimed at improving cancer treatment outcomes.
When are the investor conferences happening?
The conferences are set for November 10 and November 13, with management presenting their insights on upcoming innovations.
Can I access the conference presentations online?
Yes, NANOBIOTIX will offer live webcasts of the presentations, which will also be available for replay on their website.
Where is NANOBIOTIX headquartered?
NANOBIOTIX is headquartered in Paris, France, but has a strong operational presence in Cambridge, Massachusetts, USA.
What is NANOBIOTIX's stock ticker symbol?
The stock ticker symbols for NANOBIOTIX are Euronext: NANO and NASDAQ: NBTX.
